In Brief: Sanofi Diagnostics Pasteur
This article was originally published in The Gray Sheet
Executive Summary
Sanofi Diagnostics Pasteur: Releases myoglobin assay for use on its Access automated immunoassay system. The test is a "paramagnetic-particle, chemiluminescent immunoassay for the quantitative determination of myoglobin levels in human serum or plasma EDTA," Sanofi says. The myoglobin test is the second of three cardiac assays planned for inclusion on the Access. Sanofi launched its Access CK-MB test earlier this fall ("The Gray Sheet" Oct. 16, In Brief). The firm is planning to launch a troponin-I test in 1996...You may also be interested in...
Pfizer’s US Rituximab Launched At A 24% Discount
Pfizer has launched its Ruxience rituximab biosimilar in the US at a 24% discount to the wholesale acquisition cost of the Rituxan original. The firm has also revealed that when it launches its Trazimera trastuzumab biosimilar in mid-February, it will be at a 22% discount to the Herceptin brand’s WAC.
Teva Leapfrogs Mylan And Sandoz On Linaclotide
A patent-litigation settlement that Teva has reached with Ironwood and Allergan over Linzess will allow the Israeli firm to enter the US market with the linaclotide-based constipation treatment ahead of major rivals Mylan, Sandoz, Sun Pharma and Aurobindo.
Tecentriq Disappoints In Post-Surgery Bladder Cancer
Failure is a knock-back for the blockbuster product, but Tecentriq has many more opportunities for trial success in 2020.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Medtech Insight?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: